At the news
? NEUTRALIMPACT 3/10 COURT-RULING filed Mar 1, 2026 at 19:00 ET
The court denied Epic's motions to dismiss in eight of eleven complaints in the Generic Pharmaceuticals MDL, allowing antitrust conspiracy claims over Ursodiol pricing to proceed against Epic. The court granted Epic's motions to dismiss in three complaints, including CVS Pharmacy's, because they failed to allege specific anti-competitive conduct by Epic. For CVS specifically, the dismissal eliminates a potential source of litigation exposure, but the ruling is procedural and does not resolve the broader MDL or any claims against CVS as a plaintiff.
- Epic's motions to dismiss were GRANTED as to CVS Pharmacy's complaint (20-cv-06310-CMR), finding it failed to describe any specific act by Epic regarding Ursodiol and did not plausibly allege Epic's role in any conspiracy.
- CVS Pharmacy is a plaintiff in this antitrust MDL, not a defendant, the ruling dismisses CVS's claims against Epic, a net negative for CVS's potential recovery from this litigation.
- Eight other complaints against Epic survive, meaning the overarching conspiracy litigation continues and could still impose costs on generic drug manufacturers.
- The court criticized CVS's complaint for lacking 'the least detail' and noted it only mentioned Epic in trade association membership lists and generic drug lists without tying Epic to any specific anti-competitive act.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access